Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19564847 | 0.96 | THRB (0.39) | ALDH1A1KMT2ATHRBFFAR1GAA | |
| SCHEMBL812217 | 0.95 | ALDH1A1 (0.39) | ALDH1A1KMT2ATHRBFFAR1GAA | |
| SCHEMBL19564846 | 0.91 | ALDH1A1 (0.41) | ALDH1A1KMT2ATHRBFFAR1GAA | |
| SCHEMBL812232 | 0.89 | ALDH1A1 (0.38) | ALDH1A1KMT2AGAAPOLBMAPK1 | |
| SCHEMBL24756135 | 0.89 | GAA (0.40) | ALDH1A1KMT2AGAAPOLBMAPK1 | |
| SCHEMBL19564843 | 0.87 | ALDH1A1 (0.34) | ALDH1A1KMT2ATHRBFFAR1GAA | |
| SCHEMBL16840307 | 0.87 | ALDH1A1 (0.34) | ALDH1A1KMT2AFFAR1GAAPOLB | |
| SCHEMBL19569884 | 0.86 | THRB (0.34) | ALDH1A1KMT2ATHRBPOLBMAPK1 | |
| SCHEMBL19569871 | 0.85 | ALDH1A1 (0.45) | ALDH1A1KMT2APOLBMAPK1TSHR | |
| SCHEMBL16840304 | 0.84 | ALDH1A1 (0.33) | ALDH1A1KMT2AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320984-A1 | OPTICAL COMPOSITION, CURED PRODUCT, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2017-11-09 | — | — | US | disclosed |
| US-9290597-B2 | (Meth)acrylate compound, optical composition, molded article, and optical element | CANON KABUSHIKI KAISHA (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20150175731-A1 | (METH)ACRYLATE COMPOUND, OPTICAL COMPOSITION, MOLDED ARTICLE, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2015-06-25 | — | — | US | disclosed |
| US-8829230-B2 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20140031582-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569541-B2 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20110288330-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175731-A1 | (METH)ACRYLATE COMPOUND, OPTICAL COMPOSITION, MOLDED ARTICLE, AND OPTICAL ELEMENT | SMYD2, ZYX, MMAB | ALDH1A1 921/4885KMT2A 280/4885THRB 2988/4885 |
| US-20110288330-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CENPE, AXIN2, CCNE2 | ALDH1A1 1823/4885KMT2A 1605/4885THRB 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.